Table of Content

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights


2. Assumptions and Research Methodology

2.1. Assumptions and Acronyms Used

2.2. Research Methodology


3. Executive Summary

3.1. Global Hepatorenal Syndrome Treatment Market: Market Snapshot


4. Market Overview

4.1. Global Hepatorenal Syndrome Treatment Market: Type Overview

4.2. Global Hepatorenal Syndrome Treatment Market: Key Industry Developments

4.3. Market Dynamics

4.4. Drivers and Restraints Snapshot Analysis

4.5. Drivers

4.5.1. Fast track and orphan drug designations

4.5.2. Increase in strategic collaboration among key players

4.6. Restraints

4.6.1. Side-effects and risks related to drug usage

4.6.2. Stringent regulatory requirements

4.7. Opportunities

4.8. Global Hepatorenal Syndrome Treatment Market Revenue Projections (US$ Mn), 2017–2027


5. Key Insights

5.1. Pipeline Analysis

5.2. Regulatory Scenario by Region/Country

5.3. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc)

5.4. Prevalence of Liver & Kidney Diseases by Region/Globally


6. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

6.1. Introduction

6.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

6.2.1. Type 1 Hepatorenal Syndrome

6.2.2. Type 2 Hepatorenal Syndrome

6.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

6.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Type


7. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

7.1. Introduction

7.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

7.2.1. Therapeutics

7.2.1.1. Terlivaz

7.2.1.2. Glypressin

7.2.1.3. Lucassin

7.2.1.4. Hepatoren

7.2.2. Surgical Treatment

7.2.2.1. Liver Transplantation

7.2.2.2. Surgical Shunting

7.2.2.2.1. Peritoneovenous Shunting

7.2.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

7.2.2.2.3. Others

7.2.2.3. Renal Replacement Therapy

7.2.2.4. Others

7.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

7.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Treatment


8. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

8.1. Introduction

8.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

8.2.1. Hospitals & Clinics

8.2.2. Ambulatory Surgical Centers

8.2.3. Academic & Research Institutes

8.2.4. Others

8.3. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

8.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by End-user


9. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

9.1. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Region, 2017–2027

9.1.1. North America

9.1.2. Europe

9.1.3. Asia Pacific

9.1.4. Latin America

9.1.5. Middle East & Africa

9.2. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

9.3. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Region


10. North America Hepatorenal Syndrome Treatment Market Analysis

10.1. North America Hepatorenal Syndrome Treatment Market

10.2. North America Hepatorenal Syndrome Treatment Market Overview

10.3. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

10.3.1. Type 1 Hepatorenal Syndrome

10.3.2. Type 2 Hepatorenal Syndrome

10.4. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

10.4.1. Therapeutics

10.4.1.1. Terlivaz

10.4.1.2. Glypressin

10.4.1.3. Lucassin

10.4.1.4. Hepatoren

10.4.2. Surgical Treatment

10.4.2.1. Liver Transplantation

10.4.2.2. Surgical Shunting

10.4.2.2.1. Peritoneovenous Shunting

10.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

10.4.2.2.3. Others

10.4.2.3. Renal Replacement Therapy

10.4.3. Others

10.5. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

10.5.1. Hospitals & Clinics

10.5.2. Ambulatory Surgical Centers

10.5.3. Academic & Research Institutes

10.5.4. Others

10.6. North America Hepatorenal Syndrome Treatment Market Forecast, by Country

10.6.1. U.S.

10.6.2. Canada

10.7. North America Hepatorenal Syndrome Treatment Market Attractiveness Analysis

10.7.1. By Type

10.7.2. By Treatment

10.7.3. By End-user

10.7.4. By Country


11. Europe Hepatorenal Syndrome Treatment Market Analysis

11.1. Europe Hepatorenal Syndrome Treatment Market

11.2. Europe Hepatorenal Syndrome Treatment Market Overview

11.3. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

11.3.1. Type 1 Hepatorenal Syndrome

11.3.2. Type 2 Hepatorenal Syndrome

11.4. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

11.4.1. Therapeutics

11.4.1.1. Terlivaz

11.4.1.2. Glypressin

11.4.1.3. Lucassin

11.4.1.4. Hepatoren

11.4.2. Surgical Treatment

11.4.2.1. Liver Transplantation

11.4.2.2. Surgical Shunting

11.4.2.2.1. Peritoneovenous Shunting

11.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

11.4.2.2.3. Others

11.4.2.3. Renal Replacement Therapy

11.4.3. Others

11.5. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

11.5.1. Hospitals & Clinics

11.5.2. Ambulatory Surgical Centers

11.5.3. Academic & Research Institutes

11.5.4. Others

11.6. Europe Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

11.6.1. U.K.

11.6.2. France

11.6.3. Germany

11.6.4. Spain

11.6.5. Italy

11.6.6. Rest of Europe

11.7. Europe Hepatorenal Syndrome Treatment Market Attractiveness Analysis

11.7.1. By Type

11.7.2. By Treatment

11.7.3. By End-user

11.7.4. By Country/Sub-region

12. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis

12.1. Asia Pacific Hepatorenal Syndrome Treatment Market Key Findings

12.2. Asia Pacific Hepatorenal Syndrome Treatment Market Overview

12.3. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

12.3.1. Type 1 Hepatorenal Syndrome

12.3.2. Type 2 Hepatorenal Syndrome

12.4. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

12.4.1. Therapeutics

12.4.1.1. Terlivaz

12.4.1.2. Glypressin

12.4.1.3. Lucassin

12.4.1.4. Hepatoren

12.4.2. Surgical Treatment

12.4.2.1. Liver Transplantation

12.4.2.2. Surgical Shunting

12.4.2.2.1. Peritoneovenous Shunting

12.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

12.4.2.2.3. Others

12.4.2.3. Renal Replacement Therapy

12.4.3. Others

12.5. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

12.5.1. Hospitals & Clinics

12.5.2. Ambulatory Surgical Centers

12.5.3. Academic & Research Institutes

12.5.4. Others

12.6. Asia Pacific Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

12.6.1. China

12.6.2. India

12.6.3. Japan

12.6.4. Australia & New Zealand

12.6.5. Rest of Asia Pacific

12.7. Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness Analysis

12.7.1. By Type

12.7.2. By Treatment

12.7.3. By End-user

12.7.4. By Country/Sub-region


13. Latin America Hepatorenal Syndrome Treatment Market Analysis

13.1. Latin America Hepatorenal Syndrome Treatment Market Key Findings

13.2. Latin America Hepatorenal Syndrome Treatment Market Overview

13.3. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

13.3.1. Type 1 Hepatorenal Syndrome

13.3.2. Type 2 Hepatorenal Syndrome

13.4. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

13.4.1. Therapeutics

13.4.1.1. Terlivaz

13.4.1.2. Glypressin

13.4.1.3. Lucassin

13.4.1.4. Hepatoren

13.4.2. Surgical Treatment

13.4.2.1. Liver Transplantation

13.4.2.2. Surgical Shunting

13.4.2.2.1. Peritoneovenous Shunting

13.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

13.4.2.2.3. Others

13.4.2.3. Renal Replacement Therapy

13.4.3. Others

13.5. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

13.5.1. Hospitals & Clinics

13.5.2. Ambulatory Surgical Centers

13.5.3. Academic & Research Institutes

13.5.4. Others

13.6. Latin America Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

13.6.1. Brazil

13.6.2. Mexico

13.6.3. Rest of Latin America

13.7. Latin America Hepatorenal Syndrome Treatment Market Attractiveness Analysis

13.7.1. By Type

13.7.2. By Treatment

13.7.3. By End-user

13.7.4. By Country/Sub-region


14. Middle East & Africa Hepatorenal Syndrome Treatment Market Analysis

14.1. Middle East & Africa Hepatorenal Syndrome Treatment Market

14.2. Middle East & Africa Hepatorenal Syndrome Treatment Market Overview

14.3. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

14.3.1. Type 1 Hepatorenal Syndrome

14.3.2. Type 2 Hepatorenal Syndrome

14.4. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

14.4.1. Therapeutics

14.4.1.1. Terlivaz

14.4.1.2. Glypressin

14.4.1.3. Lucassin

14.4.1.4. Hepatoren

14.4.2. Surgical Treatment

14.4.2.1. Liver Transplantation

14.4.2.2. Surgical Shunting

14.4.2.2.1. Peritoneovenous Shunting

14.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

14.4.2.2.3. Others

14.4.2.3. Renal Replacement Therapy

14.4.3. Others

14.5. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

14.5.1. Hospitals & Clinics

14.5.2. Ambulatory Surgical Centers

14.5.3. Academic & Research Institutes

14.5.4. Others

14.6. Middle East & Africa Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

14.6.1. GCC Countries

14.6.2. South Africa

14.6.3. Rest of Middle East & Africa

14.7. Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness Analysis

14.7.1. By Type

14.7.2. By Treatment

14.7.3. By End-user

14.7.4. By Country/Sub-region


15. Competitive Landscape

15.1. Company Profiles

15.1.1. Cumberland Pharmaceuticals, Inc.

15.1.1.1. Overview (HQ, Employee Strength, Business Segments)

15.1.1.2. Financials

15.1.1.3. Recent Developments

15.1.1.4. Strategy

15.1.2. Orphan Therapeutics, LLC.

15.1.2.1. Overview (HQ, Employee Strength, Business Segments)

15.1.2.2. Financials

15.1.2.3. Recent Developments

15.1.2.4. Strategy

15.1.3. BioVie Inc.

15.1.3.1. Overview (HQ, Employee Strength, Business Segments)

15.1.3.2. Financials

15.1.3.3. Recent Developments

15.1.3.4. Strategy

15.1.4. Mallinckrodt Pharmaceuticals

15.1.4.1. Overview (HQ, Employee Strength, Business Segments)

15.1.4.2. Financials

15.1.4.3. Recent Developments

15.1.4.4. Strategy



List of Figures



FIG. 1 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

FIG. 2 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type (2018)

FIG. 3 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment (2018)

FIG. 4 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user (2018)

FIG. 5 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region (2018)

FIG. 6 Regulatory Approval Process - U.S.

FIG. 7 Regulatory Approval Process - Europe

FIG. 8 Regulatory Approval Process - Japan

FIG. 9 Regulatory Approval Process - China

FIG. 10 Revision of Drug Administration Law & Drug Registration Regulation

FIG. 11 Drug Approval Process in China - Step 1

FIG. 12 Drug Approval Process in China - Step 2

FIG. 13 Drug Approval Process in China - Step 3

FIG. 14 Recent CFDA Regulatory Reforms to Support Innovative Drugs

FIG. 15 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type, 2018 and 2027

FIG. 16 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Type, 2019–2027

FIG. 17 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 1 Hepatorenal Syndrome, 2017–2027

FIG. 18 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 2 Hepatorenal Syndrome, 2017–2027

FIG. 19 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment, 2018 and 2027

FIG. 20 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Treatment, 2019–2027

FIG. 21 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Therapeutics, 2017–2027

FIG. 22 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Treatment, 2017–2027

FIG. 23 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user, 2018 and 2027

FIG. 24 Global Hepatorenal Syndrome Treatment Market Attractiveness, by End-user, 2019–2027

FIG. 25 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals & Clinics, 2017–2027

FIG. 26 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2017–2027

FIG. 27 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Academic & Research Institutes, 2017–2027

FIG. 28 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

FIG. 29 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region, 2018 and 2027

FIG. 30 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Region, 2019–2027

FIG. 31 North America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 32 North America Hepatorenal Syndrome Treatment Market Value Share (%), by Country, 2018 and 2027

FIG. 33 North America Hepatorenal Syndrome Treatment Market Attractiveness, by Country, 2019–2027

FIG. 34 Europe Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 35 Europe Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 36 Europe Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 37 Asia Pacific Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 38 Asia Pacific Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 39 Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 40 Latin America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 41 Latin America Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 42 Latin America Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 46 Cumberland Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

FIG. 47 Cumberland Pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2018

FIG. 48 Mallinckrodt Pharmaceuticals, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

FIG. 49 Mallinckrodt Pharmaceuticals, R&D Expenses, 2015–2018

FIG. 50 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Region, 2018

FIG. 51 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Business Segment, 2018


List of Tables



TABLE 1 Global Hepatorenal Syndrome Treatment Pipeline Analysis (1/5)

TABLE 2 Global Hepatorenal Syndrome Treatment Pipeline Analysis (2/5)

TABLE 3 Global Hepatorenal Syndrome Treatment Pipeline Analysis (3/5)

TABLE 4 Global Hepatorenal Syndrome Treatment Pipeline Analysis (4/5)

TABLE 5 Global Hepatorenal Syndrome Treatment Pipeline Analysis (5/5)

TABLE 6 Comparative Analysis of Orphan Drug Policies

TABLE 7 Worldwide Epidemiology of Liver Diseases

TABLE 8 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 9 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 10 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 11 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 12 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 13 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 14 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

TABLE 15 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

TABLE 16 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 17 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 18 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 19 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 20 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 21 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 22 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 23 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 24 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 25 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 26 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 27 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 28 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 29 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 30 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 31 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 32 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 33 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 34 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 35 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 36 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 37 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 38 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 39 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 40 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 41 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 42 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 46 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 47 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 48 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 49 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027